UB Paderborn / Katalog / Suche / in CDI

New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group

HemaSphere, 2024-04, Vol.8 (4), p.e70-n/a

2024

Volltextzugriff (PDF)

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia

Leukemia & lymphoma, 2018-07, Vol.59 (7), p.1634-1643

2018

Volltextzugriff (PDF)

Fibrinogen Deficiency with Thrombotic Manifestations

European journal of case reports in internal medicine, 2022-06, Vol.9 (6), p.003400-003400

2022

Volltextzugriff (PDF)

Full Characterization of Thrombotic Events in All Hospitalized COVID-19 Patients in a Spanish Tertiary Hospital during the First 18 Months of the Pandemic

Journal of clinical medicine, 2022-06, Vol.11 (12), p.3443

2022

Volltextzugriff (PDF)

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Blood, 2021-04, Vol.137 (14), p.1879-1894

2021

Volltextzugriff (PDF)

POSTER: ABCL-479 17P (TP53) Deletion Determines Worse Survival in Diffuse Large B-Cell Lymphoma Patients After First-Line Treatment With Immunochemotherapy: A Retrospective Study of 151 Patients

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S202-S202

2023

Volltextzugriff (PDF)

ABCL-479 17P (TP53) Deletion Determines Worse Survival in Diffuse Large B-Cell Lymphoma Patients After First-Line Treatment With Immunochemotherapy: A Retrospective Study of 151 Patients

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S435-S436

2023

Volltextzugriff (PDF)

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis

PloS one, 2017-03, Vol.12 (3), p.e0172978-e0172978

2017

Volltextzugriff (PDF)

Neurological Comorbidity Is a Predictor of Death in Covid-19 Disease: A Cohort Study on 576 Patients

Frontiers in neurology, 2020-07, Vol.11, p.781-781

2020

Volltextzugriff (PDF)

Evaluation of Cytokines as Robust Diagnostic Biomarkers for COVID-19 Detection

Journal of personalized medicine, 2021-07, Vol.11 (7), p.681

2021

Volltextzugriff (PDF)

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

American journal of hematology, 2015-03, Vol.90 (3), p.E40-E43

2015

Volltextzugriff (PDF)

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

Blood, 2010-11, Vol.116 (21), p.1237-1237

2010

Volltextzugriff (PDF)

Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial

Haematologica (Roma), 2005-10, Vol.90 (10), p.1346-1356

2005

Volltextzugriff (PDF)

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response

Blood, 2009-11, Vol.114 (22), p.1121-1121

2009

Volltextzugriff (PDF)

Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice

Blood, 2015-12, Vol.126 (23), p.2263-2263

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

ERG, EVI1 and PRAME Are Relevant Markers of Treatment Response and Survival, and They Could Be Useful for Improving the Risk-Stratification in Citogenetically Normal Acute Myeloid Leukemia (CN-AML)

R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia

Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis

Fibrinogen Deficiency with Thrombotic Manifestations

Full Characterization of Thrombotic Events in All Hospitalized COVID-19 Patients in a Spanish Tertiary Hospital during the First 18 Months of the Pandemic

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

POSTER: ABCL-479 17P (TP53) Deletion Determines Worse Survival in Diffuse Large B-Cell Lymphoma Patients After First-Line Treatment With Immunochemotherapy: A Retrospective Study of 151 Patients

ABCL-479 17P (TP53) Deletion Determines Worse Survival in Diffuse Large B-Cell Lymphoma Patients After First-Line Treatment With Immunochemotherapy: A Retrospective Study of 151 Patients

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis

Ibrutinib in Combination with R-Gemox-D in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase II Clinical Trial of the Geltamo Group

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

Neurological Comorbidity Is a Predictor of Death in Covid-19 Disease: A Cohort Study on 576 Patients

Evaluation of Cytokines as Robust Diagnostic Biomarkers for COVID-19 Detection

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months

Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC)

Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response

Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice

Identification By Whole Exome Sequencing of the Molecular Defect in a Novel Gene Related to Glycosylation in Two Unrelated Families with Syndromic Macrothrombocytopenia

Suchergebnisse filtern